Exelixis

YTD

ALL

Trade Exelixis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About EXEL

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.

CEO

Michael M. Morrissey

CEOMichael M. Morrissey

Employees

1,077

Employees1,077

Headquarters

Alameda, California

HeadquartersAlameda, California

Founded

1994

Founded1994

Employees

1,077

Employees1,077

EXEL Key Statistics

Market cap

13.01B

Market cap13.01B

Price-Earnings ratio

17.10

Price-Earnings ratio17.10

Dividend yield

—

Dividend yield—

Average volume

2.50M

Average volume2.50M

High today

$52.34

High today$52.34

Low today

$50.89

Low today$50.89

Open price

$51.95

Open price$51.95

Volume

346.66K

Volume346.66K

52 Week high

$52.96

52 Week high$52.96

52 Week low

$33.76

52 Week low$33.76

Stock Snapshot

The current Exelixis(EXEL) stock price is $51.75, with a market capitalization of 13.01B. The stock trades at a price-to-earnings (P/E) ratio of 17.10.

During the trading session on 2026-06-04, Exelixis(EXEL) shares reached a daily high of $52.34 and a low of $50.89. At a current price of $51.75, the stock is +1.7% higher than the low and still -1.1% under the high.

Trading volume for Exelixis(EXEL) stock has reached 346.66K, versus its average volume of 2.5M.

Over the past 52 weeks, Exelixis(EXEL) stock has traded between a high of $52.96 and a low of $33.76.

EXEL News

Investing.com 14h

Exelixis director Jack Wyszomierski sells $198,408 in shares - Investing.com

...

TipRanks 4d

Exelixis announces results from subgroup analysis of Phase 3 Cabinet trial

Exelixis (EXEL) announced results from a subgroup analysis of the phase 3 Cabinet trial, which showed that Cabometyx provided significant improvements in progre...

TipRanks 6d

Exelixis Shareholders Approve Equity Plan and Board Slate

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

Analyst ratings

45%

of 20 ratings

Buy

45%

Hold

45%

Sell

10%

More EXEL News

TipRanks 7d

Top Exelixis Insider Makes a Major Move With Company Stock

New insider activity at Exelixis ( (EXEL) ) has taken place on May 28, 2026. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ra...

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.